医学
药物遗传学
噻唑烷二酮
药理学
药品
糖尿病
药物治疗
不利影响
生物信息学
2型糖尿病
2型糖尿病
内科学
内分泌学
基因
生物
遗传学
基因型
作者
Chiranjib Chakraborty,Minna J. Hsu,Govindasamy Agoramoorthy
出处
期刊:Current Drug Metabolism
[Bentham Science]
日期:2015-12-10
被引量:1
标识
DOI:10.2174/138920021610151210183821
摘要
The type 2 diabetes or T2D mellitus has turn into an epidemic throughout the globe in recent years. Various forms of treatment modalities have been available for patients with T2D with some major classes of approved drugs that include Sulfonylureas, Meglitinides, Biguanides, Thiazolidinedione, Alpha-glucosidase inhibitors, GLP-1 analogs, DPP-4 Inhibitors, and SGLT2 inhibitors. This review focuses on the drug metabolizing enzymes (DME), gene polymorphisms, and inter-individual variability in therapeutics including adverse reaction effects involving Phase-I DME and Phase-II in general. This review also covers some key anti-diabetic drugs with respect to their pharcogenomics.
科研通智能强力驱动
Strongly Powered by AbleSci AI